PT1795186E - Preparado farmacêutico compreendendo flupirtina com libertação controlada da substância activa - Google Patents

Preparado farmacêutico compreendendo flupirtina com libertação controlada da substância activa Download PDF

Info

Publication number
PT1795186E
PT1795186E PT60229853T PT06022985T PT1795186E PT 1795186 E PT1795186 E PT 1795186E PT 60229853 T PT60229853 T PT 60229853T PT 06022985 T PT06022985 T PT 06022985T PT 1795186 E PT1795186 E PT 1795186E
Authority
PT
Portugal
Prior art keywords
flupirtin
active agent
controlled release
medicament formulation
medicament
Prior art date
Application number
PT60229853T
Other languages
English (en)
Inventor
Joachim Wolf
Bernd Terhaag
Asal Qadan
Barbara Faustmann
Original Assignee
Teva Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37908079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1795186(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Gmbh filed Critical Teva Gmbh
Publication of PT1795186E publication Critical patent/PT1795186E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT60229853T 2005-11-08 2006-11-04 Preparado farmacêutico compreendendo flupirtina com libertação controlada da substância activa PT1795186E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005054610A DE102005054610B4 (de) 2005-11-08 2005-11-08 Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
PT1795186E true PT1795186E (pt) 2014-01-22

Family

ID=37908079

Family Applications (1)

Application Number Title Priority Date Filing Date
PT60229853T PT1795186E (pt) 2005-11-08 2006-11-04 Preparado farmacêutico compreendendo flupirtina com libertação controlada da substância activa

Country Status (8)

Country Link
EP (1) EP1795186B2 (pt)
CY (1) CY1115709T1 (pt)
DE (1) DE102005054610B4 (pt)
DK (1) DK1795186T4 (pt)
ES (1) ES2443468T5 (pt)
PL (1) PL1795186T5 (pt)
PT (1) PT1795186E (pt)
RU (1) RU2352338C2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350009B1 (en) * 2008-06-09 2016-03-16 TEVA GmbH Sulfonate salts of flupirtine
US8183267B2 (en) 2008-06-09 2012-05-22 Awd. Pharma Gmbh & Co. Kg Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine
DE102008051783A1 (de) * 2008-10-17 2010-04-22 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Valsartan enthaltende Tablette
TW201311690A (zh) 2011-08-09 2013-03-16 Hydra Biosciences Inc 抑制暫態受體電位離子通道ｔｒｐａ１
JP2015508789A (ja) * 2012-03-02 2015-03-23 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 医薬製剤
WO2014026073A1 (en) * 2012-08-09 2014-02-13 Cubist Pharmaceuticals, Inc. Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
DE102013014417A1 (de) 2013-08-29 2015-03-05 Klinipharm Gmbh Schwammkollagen umfassende Zubereitungen mit definiertem in vivo-Freisetzungsprofil vor allem im Colon, deren Herstellung und Verwendung
CN109806233B (zh) * 2017-11-21 2022-05-20 北京泰德制药股份有限公司 一种含有氟吡汀或其药用盐的组合物及其制备方法
RU2680244C1 (ru) * 2017-12-28 2019-02-19 Общество С Ограниченной Ответственностью "Валента-Интеллект" Комбинации флупиртина и циклобензаприна для лечения болевых синдромов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
DE10328260A1 (de) * 2003-06-23 2005-01-27 Schmidt, K.-G., Dr. med. Flupirtine-Präparat
EP1799264A2 (en) * 2004-10-08 2007-06-27 Neuromolecular Pharmaceuticals Inc Methods and compositions for treating migraine pain

Also Published As

Publication number Publication date
DE102005054610B4 (de) 2010-06-10
CY1115709T1 (el) 2017-01-25
PL1795186T5 (pl) 2018-05-30
DK1795186T4 (en) 2018-03-05
DK1795186T3 (da) 2014-01-27
EP1795186B2 (de) 2017-12-06
ES2443468T5 (es) 2018-03-26
EP1795186A3 (de) 2007-10-24
DE102005054610A1 (de) 2007-07-12
PL1795186T3 (pl) 2014-05-30
RU2352338C2 (ru) 2009-04-20
EP1795186A2 (de) 2007-06-13
RU2006139127A (ru) 2008-05-20
EP1795186B1 (de) 2013-10-23
ES2443468T3 (es) 2014-02-19

Similar Documents

Publication Publication Date Title
PL1795186T3 (pl) Preparat leku zawierający flupirtynę o kontrolowanym uwalnianiu substancji czynnej
HK1244819A1 (zh) Foxm1肽和包含foxm1肽的藥劑
PL2205081T3 (pl) Kombinacje substancji czynnych o właściwościach owadobójczych i roztoczobójczych
EP1884513A4 (en) PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME
IL186194A0 (en) Markers associated with the therapeutic efficacy of glatiramer acetate
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
ZA200900661B (en) Active ingredient combination with insecticidal and acaricidal properties
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
EP2093237A4 (en) ANTICANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
PT1850664E (pt) Formulação de cápsulas
ZA200804477B (en) Agrochemical nanoparticulate active ingredient formulations
ZA200810455B (en) Active agent combinations with insecticidal and acaricidal properties
IL196394A0 (en) Implantable sustained drug delivery device for releasing active agents to the osteomeatal complex
GB0524958D0 (en) Transdermal administration of active agents
ZA200808162B (en) Active ingredient combinations with insecticidal properties
ZA200804427B (en) Nanoparticulate active ingredient formulations
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
EP1753405A4 (en) SLOW RELEASE PHARMACEUTICAL PREPARATION
PL2194784T3 (pl) Kombinacje substancji czynnych o właściwościach owadobójczych i roztoczobójczych
EP2098228A4 (en) ANTI-INFLAMMATORY AGENT CONTAINING 2-AMINOPHENOL OR A DERIVATIVE THEREOF AS ACTIVE INGREDIENT
IL199168A0 (en) Indolizine derivatives and the use thereof as antidiabetics
IL195815A0 (en) Active agent combinations with insecticidal and acaricidal properties
ZA201000487B (en) Formulation for the release of bioactive substances and use thereof as a pest control agent
EP2006287A4 (en) COMPOUND HAVING ANTIMALARIAL ACTIVITY AND ANTIMALARIAL DRUG CONTAINING IT AS AN ACTIVE SUBSTANCE
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS